Steven Gilmore

ORCID: 0009-0007-4064-5785
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Protein Structure and Dynamics
  • Neutropenia and Cancer Infections
  • thermodynamics and calorimetric analyses
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Chemotherapy-related skin toxicity
  • Economic and Financial Impacts of Cancer
  • Hemoglobin structure and function
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Radiopharmaceutical Chemistry and Applications
  • Genomics and Chromatin Dynamics
  • Bone health and treatments
  • Cutaneous Melanoma Detection and Management
  • Childhood Cancer Survivors' Quality of Life
  • Bacterial Identification and Susceptibility Testing
  • Oral health in cancer treatment
  • Methemoglobinemia and Tumor Lysis Syndrome
  • Viral Infectious Diseases and Gene Expression in Insects
  • Computational Drug Discovery Methods
  • Erythropoietin and Anemia Treatment
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Neonatal Health and Biochemistry
  • Pelvic floor disorders treatments
  • Gene Regulatory Network Analysis
  • Medicine and Dermatology Studies History

McKesson (United States)
2023-2024

The US Oncology Network
2023-2024

Queen's University
2023

Johns Hopkins Hospital
2017-2021

Sidney Kimmel Comprehensive Cancer Center
2017-2019

Corewell Health Blodgett Hospital
2018

Spectrum Health
2018

Oregon Health and Science University Hospital
2018

Alaska Native Tribal Health Consortium
2018

Skin and Cancer Foundation
2016

Abstract Purpose Taxanes are a cornerstone treatment in early and advanced stage breast cancer other common solid tumor malignancies; however, the development of chemotherapy induced peripheral neuropathy (CIPN) often necessitates dose-reduction, which may hamper effectiveness drug compromise survival outcomes especially when used adjuvant setting. Limited literature is available on prevalence severity dose reduction due to CIPN. We sought determine frequency CIPN-induced patients who...

10.1186/2193-1801-3-366 article EN SpringerPlus 2014-07-16

Long-range intraprotein interactions give rise to many important protein behaviors. Understanding how energy is transduced through structures either transmit a signal or elicit conformational changes therefore current challenge in structural biology. In an effort understand such linkages, multiple V → A mutations were made the small globular eglin c. The physical responses, as mapped by NMR spin relaxation, residual dipolar couplings (RDCs), and scalar couplings, illustrate that interior of...

10.1021/bi060652l article EN Biochemistry 2006-06-01

To present a position statement from the Hematology/Oncology Pharmacy Association (HOPA) that pertains to dose rounding of biologic and cytotoxic anticancer agents.The HOPA Standards Committee organized work group oncology pharmacist specialists examine safety value agents. Primary literature describes methods for rounding, with clinical or economic data, were analyzed. Relevant pharmacokinetic characteristics aspects product formulation considered. Issues institutional application...

10.1200/jop.2017.025411 article EN Journal of Oncology Practice 2018-02-05

This study documents the perspectives of Australian dermatologists on adequacy teaching and training in skin colour (SOC), their confidence diagnosing treating common medical, surgical cosmetic issues SOC to gauge desire for further this area.Surveys were distributed Australasian Dermatologists during annual scientific meeting Melbourne, Australia 2014. Completed surveys from nationwide collected evaluated. Altogether 270 distributed.In total, 140 completed returned. Four excluded as they by...

10.1111/ajd.12556 article EN Australasian Journal of Dermatology 2016-12-09

The solution structure and dynamics of the BRCT domain from human DNA polymerase μ, implicated in repair chromosome breaks by nonhomologous end joining (NHEJ), has been determined using NMR methods. domains are typically involved protein−protein interactions between factors required for cellular response to damage. pol μ is atypical that, unlike other reported structures, neither part a tandem grouping, nor does it appear form stable homodimers. Although sequence some unique characteristics,...

10.1021/bi7007728 article EN Biochemistry 2007-10-01

Methotrexate has a wide dosing range. High-dose methotrexate is dose of 1000 mg/m2 or greater. In the 1970s, incidence mortality associated with ranged from 4.6 to 6%. 2012, University Maryland Medical Center implemented standardized high-dose protocol. The purpose this study was evaluate whether institution followed recommendations based on Bleyer nomogram for administration more closely after implementation protocol.In retrospective chart review, 37 patients received 119 cycles before...

10.1177/1078155217729744 article EN Journal of Oncology Pharmacy Practice 2017-09-25

11182 Background: Timing of biomarker results is critical to informing the selection appropriate precision medicine-based treatment options for patients. Prior studies have demonstrated that low rates testing may be driven by poor documentation. Our clinical decision support (CDS) tool aims provide community oncology clinicians with a clear picture ever-growing available treatments. Evaluation CDS data revealed an excess documented as “unknown” thought related availability. Methods: During...

10.1200/jco.2024.42.16_suppl.11182 article EN Journal of Clinical Oncology 2024-06-01

e19565 Background: OM is a common complication of high-dose melphalan in MM patients (pts). Proposed risk factors for SCT include: low albumin and high serum creatinine (Cr) levels, both were evaluated undergoing Mel/ASCT. (Grazziutti, ML, Bone Marrow Transplant 2006). Methods: This single center retrospective chart review 214 sequentially treated pts who received Mel 200mg/m2 conditioning prior to between January 2005-September 2011. Data collected included: demographics, Hgb, Cr,...

10.1200/jco.2012.30.15_suppl.e19565 article EN Journal of Clinical Oncology 2012-05-20

e20574 Background: CIPN is a common and potentially dose-limiting complication of many effective cytotoxic agents. Taxanes are the cornerstone treatment in BC. Limited data available regarding prevalence severity DR due to following taxane use. Methods: Charts 123 consecutive newly diagnosed BC pts treated with as part standard neoadjuvant/adjuvant chemotherapy at University Maryland Greenebaum Cancer Center between 01/01/2008 12/31/2011 were reviewed. Treating physicians followed...

10.1200/jco.2013.31.15_suppl.e20574 article EN Journal of Clinical Oncology 2013-05-20

Single, fixed-dose rasburicase administration has been evaluated as an effective strategy in the management of hyperuricemia hospital setting, but this not yet described within ambulatory community oncology practices. The objective study is to evaluate and optimize dosing for tumor lysis syndrome (TLS)-associated US Oncology Network (The Network).

10.1177/10781552231190005 article EN Journal of Oncology Pharmacy Practice 2023-08-10

509 Background: NCCN Guidelines recommend erythropoietic stimulating agents (ESAs) to manage symptomatic anemia in patients with lower-risk myelodysplastic syndrome (MDS) and serum EPO ≤500 mU/mL. Epoetin alfa darbepoetin have been used a variety of dosing strategies clinical practice, often require dose adjustments achieve an optimal response, including transfusion independence. The objective this study was increase concordance guidelines supported initial subsequent doses ESAs US Oncology...

10.1200/op.2023.19.11_suppl.509 article EN JCO Oncology Practice 2023-10-26

Purpose Pegfilgrastim is indicated to reduce the risk of febrile neutropenia. As a cost-savings initiative, Process Guidelines were developed and implemented at large, academic teaching institution improve appropriate use pegfilgrastim decrease costs outpatient infusion center administration by deferring doses home self-administration for eligible patients. Methods A retrospective medical record review was conducted post-implementation Guideline evaluate assess safety efficacy transferring...

10.1177/1078155217722046 article EN Journal of Oncology Pharmacy Practice 2017-08-07

10.17615/awsn-nn82 article EN Carolina Digital Repository (University of North Carolina at Chapel Hill) 2006-01-01

Introduction Denosumab (Xgeva ® ) and zoledronic acid (Zometa are widely utilized for prevention of skeletal related events (SREs) in oncology patients. Drug costs, renal function, ease logistics administration, adverse effect profile factors frequently considered by patients and/or providers when selecting an optimal agent. Given the significantly higher drug cost denosumab compared to acid, evaluation our institution's use investigation into opportunities shift administrations lower...

10.1177/10781552211052514 article EN Journal of Oncology Pharmacy Practice 2021-11-05
Coming Soon ...